索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]刘 鹏 黄晓曦.胃黏膜相关淋巴组织淋巴瘤的研究进展[J].国际消化病杂志,2018,01:1-5.
点击复制

胃黏膜相关淋巴组织淋巴瘤的研究进展(PDF)

《国际消化病杂志》[ISSN:1673-534X/CN:31-1953/R]

期数:
2018年01期
页码:
1-5
栏目:
综述
出版日期:
2018-02-25

文章信息/Info

Title:
-
作者:
刘 鹏 黄晓曦
570100 中南大学湘雅医学院附属海口医院消化内科
Author(s):
-
关键词:
胃黏膜相关淋巴组织淋巴瘤;  幽门螺杆菌;  治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-534X.2018.01.001
文献标识码:
-
摘要:
胃黏膜相关淋巴组织(MALT)淋巴瘤属淋巴结外边缘区与黏膜相关的一种非霍奇金淋巴瘤,其发病机制与幽门螺杆菌(Hp)感染有关。胃MALT淋巴瘤临床表现缺乏特异性,内镜检查是诊断的主要手段,病理诊断则是其诊断的金标准。根除Hp为治疗的首要措施,而放射治疗和化学治疗方案在疾病早期也具有重要意义,治疗后的内镜随访对监测疾病复发具有重要作用。
Abstract:
-

参考文献/References

1 Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma[J]. Cancer, 1983, 52(8): 1410-1416.
2 禹晶, 张秉全, 林佰艳, 等. 胃黏膜相关淋巴组织淋巴瘤临床与胃镜表现分析[J]. 胃肠病学和肝病学杂志, 2014, 23(9): 998-1000.
3 Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma[J]. N Engl J Med, 1994, 330(18): 1267-1271.
4 Venerito M, Vasapolli R, Malfertheiner P. Helicobacter pylori and gastric cancer: timing and impact of preventive measures[J]. Adv Exp Med Biol, 2016, 908: 409-418.
5 Nakamura S, Matsumoto T, Iida M, et al. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends[J]. Cancer, 2003, 97(10): 2462-2473.
6 Matsushita H, Asai S, Yabe M, et al. A comprehensive diagnostic system for hematological diseases based on the WHO classification of tumors of hematopoietic and lymphoid tissues[J]. Rinsho Byori, 2011, 59(1): 65-74.
7 Wöhrer S, Troch M, Streubel B, et al. MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course[J]. Leukemia, 2007, 21(8): 1812-1818.
8 Joo M, Kwak JE, Chang SH, et al. Helicobacter heilmannii-associated gastritis: clinicopathologic findings and comparison with Helicobacter pylori-associated gastritis[J]. J Korean Med Sci, 2007, 22(1): 63-69.
9 赵昌杰, 陈林. 18例胃MALT淋巴瘤的胃镜下表现及分析[J]. 中国实用医药, 2010, 5(4): 189-190.
10 NCCN指南非霍奇金淋巴瘤专家组. 非霍奇金淋巴瘤实践指南2015中文版[DB/OL]. 第二版. 美国: 美国国家综合癌症网络公司, 2015.
11 Matsumoto H, Shiotani A, Nishibayashi H, et al. Molecular detection of H. pylori using adherent gastric mucous to biopsy forceps[J]. Helicobacter, 2016, 21(6): 548-553.
12 Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT[J]. Gut, 2011, 60(6): 747-758.
13 Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma[J]. Ann Oncol, 1994, 5(5): 397-400.
14 Zhang S, Wang L, Yu D, et al. Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution[J]. World J Surg Oncol, 2015, 13: 246.
15 Fischbach W. Gastric MALT lymphoma-update on diagnosis and treatment[J]. Best Pract Res Clin Gastroenterol, 2014, 28(6): 1069-1077.
16 Ajani JA, D'Amico TA, Almhanna K, et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2016, 14(10): 1286-1312.
17 Troch M, Streubel B, Petkov V, et al. Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up[J]. Anticancer Res, 2007, 27(5B): 3633-3637.
18 Zucca E, Copie-Bergman C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2013, 24(Suppl 6): 144-148.
19 Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: current status and future concepts[J]. World J Gastroenterol, 2014, 20(18): 5283-5293.
20 Zullo A, Hassan C, Cristofari F, et al. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma[J]. Clin Gastroenterol Hepatol, 2010, 8(2): 105-110.
21 Hancock BW, Qian W, Linch D, et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial[J]. Br J Haematol, 2009, 144(3): 367-375.
22 Copie-Bergman C, Wotherspoon AC, Capella C, et al. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice[J]. Br J Haematol, 2013, 160(1): 47-52.
23 Ye H, Dogan A, Karran L, et al. BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma[J]. Am J Pathol, 2000, 157(4): 1147-1154.
24 Lima KS, Albuquerque W, Arantes VN, et al. Helicobacter pylori and t(11; 18)(q21; q21)translocation in gastric malt lymphoma[J]. Arq Gastroenterol, 2014, 51(2): 84-89.
25 Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11; 18)(q21; q21)in MALT lymphomas of different sites: significant association with CagA strains of H.pylori in gastric MALT lymphoma[J]. Blood, 2003, 102(3): 1012-1018.
26 Pereira MI, Medeiros JA. Role of Helicobacter pylori in gastric mucosa-associated lymphoid tissue lymphomas[J]. World J Gastroenterol, 2014, 20(3): 684-698.
27 Wirth A, Gospodarowicz M, Aleman BM, et al. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study[J]. Ann Oncol, 2013, 24(5): 1344-1351.
28 Abe S, Oda I, Inaba K, et al. A retrospective study of 5-year outcomes of radiotherapy for gastric mucosa-associated lymphoid tissue lymphoma refractory to Helicobacter pylori eradication therapy[J]. Jpn J Clin Oncol, 2013, 43(9): 917-922.
29 Annibali O, Sabatino F, Mantelli F, et al. Review article: Mucosa-associated lymphoid tissue(MALT)-type lymphoma of ocular adnexa. Biology and treatment[J]. Crit Rev Oncol Hematol, 2016, 100: 37-45.
30 Wöhrer S, Kiesewetter B, Fischbach J, et al. Retrospective comparison of the effectiveness of various treatment modalities of extragastric MALT lymphoma: a single-center analysis[J]. Ann Hematol, 2014, 93(8): 1287-1295.
31 Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study[J]. J Clin Oncol, 2013, 31(5): 565-572.
32 Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial[J]. Lancet, 2013, 381(9873): 1203-1210.
33 Salar A, Domingo-Domenech E, Panizo C, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma(MALT2008-01): a multicentre, single-arm, phase 2 trial[J]. Lancet Haematol, 2014, 1(3): e104-e111.
34 Teckie S, Qi S, Lovie S, et al. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent[J]. Int J Radiat Oncol Biol Phys, 2015, 92(1): 130-137.
35 Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption[J]. Gut, 2013, 62(1): 34-42.
36 Zullo A, Hassan C, Andriani A, et al. Eradication therapy for Helicobacter pylori in patients with gastric MALT lymphoma: a pooled data analysis[J]. Am J Gastroenterol, 2009, 104(8): 1932-1937.
37 Lum SH, Bonney D, Cheesman E, et al. Successful curative therapy with rituximab and allogeneic haematopoietic stem cell transplantation for MALT lymphoma associated with STK4-mutated CD4+ lymphocytopenia[J]. Pediatr Blood Cancer, 2016, 63(9): 1657-1659.
38 Troch M, Jonak C, Müllauer L, et al. A phase Ⅱ study of bortezomib in patients with MALT lymphoma[J]. Haematologica, 2009, 94(5): 738-742.
39 Troch M, Zielinski C, Raderer M. Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue(MALT lymphoma)[J]. Ann Oncol, 2009, 20(8): 1446-1447.
40 Kiesewetter B, Troch M, Dolak W, et al. A phase Ⅱ study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue(MALT lymphoma)[J]. Haematologica, 2013, 98(3): 353-356.
41 Kiesewetter B, Willenbacher E, Willenbacher W, et al. A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma[J]. Blood, 2017, 129(3): 383-385.
42 Govi S, Dognini GP, Licata G, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase Ⅱ trial[J]. Br J Haematol, 2010, 150(2): 226-229.

备注/Memo

备注/Memo:
作者单位:570100 中南大学湘雅医学院附属海口医院消化内科
通信作者:黄晓曦,Email: 9701234@qq.com
更新日期/Last Update: 2018-02-25